NAVITOCLAX (ABT-263) PLUS FLUDARABINE/CYCLOPHOSPHAMIDE/RITUXIMAB (FCR) OR BENDAMUSTINE/RITUXIMAB (BR): A PHASE 1 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

2012

et al.

Creative Commons 'BY' version 4.0 license

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Related Items

THE BCL-2 INHIBITOR ABT-199 (GDC-0199) IS ACTIVE AND WELL-TOLERATED IN ULTRA HIGH-RISK RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
- Roberts, A;
- Davids, M;
- Pagel, J;
- Kahl, B;
- Wierda, W;
- Miller, T;
- Gerecitano, J;
- Kipps, T;
- Anderson, M;
- Huang, D;
- Darden, D;
- Gressick, L;
- Nolan, C;
- Yang, J;
- Busman, T;
- Graham, A;
- Cerri, E;
- Enschede, S;
- Humerickhouse, R;
- Seymour, J
Agnostically Learning Multi-Index Models with Queries
- Diakonikolas, Ilias;
- Kane, Daniel;
- Kontonis, Vasilis;
- Tzamos, Christos;
- Zarifis, Nikos
Association of Fetal Heart Rate Tracing with Adverse Neonatal Outcomes at 32 0/7 to 36 6/7 Weeks
- Cortes, Christina N;
- Cagino, Kristen A;
- Roberts, Aaron W;
- Wiley, Rachel L;
- Patel, Shareen;
- Zullo, Fabrizio;
- Mendez-Figueroa, Hector;
- Chauhan, Suneet P
Information-Computation Tradeoffs for Noiseless Linear Regression with Oblivious Contamination
- Diakonikolas, Ilias;
- Gao, Chao;
- Kane, Daniel;
- Lafferty, John;
- Pensia, Ankit
A wearable patch for continuous levodopa monitoring in sweat: Towards exertion and power-free pharmacodynamic assessment in Parkinson’s disease
- Saha, Tamoghna;
- Khan, Muhammad Inam;
- Longardner, Katherine;
- Sabbagh, Barak;
- Zheng, Kaiwen;
- de Mendoza, Hugo;
- Ji, Gaoyuan;
- Choi, Bumsik;
- Wang, Zongnan;
- Pham, Rosie;
- Skipworth, Michael;
- Shah, Eshita;
- Reynoso, Maria;
- Moonla, Chochanon;
- Abdal, Abdulhameed;
- Datta, Debika;
- Sandhu, Samar Singh;
- Nandhakumar, Ponnusamy;
- Jedrzak, Artur;
- Ding, Shichao;
- Yin, Lu;
- Litvan, Irene;
- Wang, Joseph

Top

UC San Diego

NAVITOCLAX (ABT-263) PLUS FLUDARABINE/CYCLOPHOSPHAMIDE/RITUXIMAB (FCR) OR BENDAMUSTINE/RITUXIMAB (BR): A PHASE 1 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)